Orion to Open New Biologics R&D Centre in Cambridge, UK
Orion Corporation is establishing a new research and development centre in Cambridge, UK in 2025 to accelerate its global growth strategy and the development of innovative medicines, focusing on biologics and large-molecule therapies. The new centre will support Orion's biologics research projects moving towards clinical phase, leveraging Europe's largest biomedical research hub and world-class scientific talent for collaboration. By reorganizing some work in Turku, Finland, Orion aims to optimize its R&D organization.
- This move underscores the strategic importance of biologics development in pharma, where innovative treatments are in high demand, and Cambridge's research ecosystem will likely play a crucial role in driving innovation forward.
- How will the integration of global talent pools and collaboration opportunities in Cambridge impact Orion's ability to stay competitive in the rapidly evolving biologics landscape?